We aimed to investigate the efficacy of standard (DRE, PSA) and advanced (mpMRI, prostate biopsy) clinical evaluation for PCa detection in patients with clinical BOO scheduled for HoLEP. This evidence concerns the gene KLK3 and posterior cortical atrophy.